Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 3
2004 4
2005 1
2007 1
2008 1
2009 1
2010 1
2011 5
2012 5
2013 3
2014 4
2015 6
2016 6
2017 2
2018 1
2019 4
2020 8
2021 6
2022 7
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
PD Med Collaborative Group; Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. PD Med Collaborative Group, et al. Lancet. 2014 Sep 27;384(9949):1196-205. doi: 10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Lancet. 2014. PMID: 24928805 Clinical Trial.
A Neurologist's Guide to REM Sleep Behavior Disorder.
Roguski A, Rayment D, Whone AL, Jones MW, Rolinski M. Roguski A, et al. Among authors: whone al. Front Neurol. 2020 Jul 8;11:610. doi: 10.3389/fneur.2020.00610. eCollection 2020. Front Neurol. 2020. PMID: 32733361 Free PMC article. Review.
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Gray R, et al. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. JAMA Neurol. 2022. PMID: 34962574 Free PMC article. Clinical Trial.
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop.
Barker RA, Björklund A, Gash DM, Whone A, Van Laar A, Kordower JH, Bankiewicz K, Kieburtz K, Saarma M, Booms S, Huttunen HJ, Kells AP, Fiandaca MS, Stoessl AJ, Eidelberg D, Federoff H, Voutilainen MH, Dexter DT, Eberling J, Brundin P, Isaacs L, Mursaleen L, Bresolin E, Carroll C, Coles A, Fiske B, Matthews H, Lungu C, Wyse RK, Stott S, Lang AE. Barker RA, et al. Among authors: whone a. J Parkinsons Dis. 2020;10(3):875-891. doi: 10.3233/JPD-202004. J Parkinsons Dis. 2020. PMID: 32508331 Free PMC article. Review.
Basal ganglia necrosis: a 'best-fit' approach.
Boca M, Lloyd K, Likeman M, Jardine P, Whone A. Boca M, et al. Among authors: whone a. Pract Neurol. 2016 Dec;16(6):458-461. doi: 10.1136/practneurol-2016-001410. Epub 2016 Aug 8. Pract Neurol. 2016. PMID: 27503951
73 results